| 2005 |
BMP9 (GDF2) crystal structure resolved to 2.3 Å; the pro-region remains tightly associated with BMP9 after secretion but does not inhibit receptor binding or biological activity in cell-based assays. ALK1 identified as a receptor for BMP9 by surface plasmon resonance (BIAcore) and functional neutralization with soluble ALK1. |
X-ray crystallography (2.3 Å), surface plasmon resonance (BIAcore), cell-based activity assays with soluble ALK1 as ligand trap |
The Journal of biological chemistry |
High |
15851468
|
| 2007 |
BMP9 binds with high affinity to ALK1 and endoglin, and weakly to ALK2 and BMPR-II/ActR-II in transfected COS cells; in endothelial cells BMP9 signals predominantly via ALK1 and BMPR-II, activating Smad1/5 and inducing ID1 protein and endoglin mRNA. BMP9 inhibits bFGF-stimulated endothelial cell proliferation/migration and blocks VEGF-induced angiogenesis. |
Receptor-binding assays in transfected COS cells, western blot (Smad1/5 phosphorylation), qRT-PCR, endothelial cell proliferation/migration assays, in vivo angiogenesis assay |
Journal of cell science |
High |
17311849
|
| 2010 |
BMP9 induces NGF expression selectively in cholinergic (Chat-positive/p75-positive) basal forebrain neurons via ALK1; secreted NGF acts in an autocrine/paracrine manner to support acetylcholine production and ChAT gene expression. BMP9-induced Ngf expression requires new protein synthesis and is blocked by BMP type I receptor inhibition. |
Primary embryonic septal cell culture, FACS isolation of cholinergic neurons (GFP/p75), RT-PCR, pharmacological inhibition of BMP type I receptors, NGF ELISA |
The Journal of neuroscience |
Medium |
20554873
|
| 2010 |
IGF-2 potentiates BMP9-induced osteogenic differentiation of mesenchymal stem cells by enhancing BMPR-Smad reporter activity and Smad1/5/8 nuclear translocation via PI3K/AKT signaling; PI3K inhibitor LY294002 abolishes this cross-talk and directly inhibits BMP9 activity. |
Alkaline phosphatase activity assay, Smad reporter assays, Smad1/5/8 nuclear translocation (immunofluorescence), pharmacological PI3K inhibition, ectopic bone formation in vivo |
Journal of bone and mineral research |
Medium |
20499340
|
| 2012 |
BMP9 is required for postnatal retinal vascular remodeling; neutralizing anti-BMP9 antibody increases retinal vascular density. BMP9 promotes endothelial quiescence and upregulates Notch pathway genes (Jagged1, Dll4, Hey1, Hey2, Hes1) while decreasing apelin expression in endothelial cells. |
Neutralizing antibody treatment in neonatal mice, Bmp9-KO mice, retinal vascular morphometry, gene expression analysis |
Blood |
High |
22566602
|
| 2012 |
BMP9 regulates the CXCL12/SDF1-CXCR4 chemokine axis in endothelial cells in an endoglin- and ALK1-dependent manner; RNA knockdown of endoglin or ALK1 impairs SDF1/CXCR4 regulation by BMP9 and impairs SDF1 expression in vivo in endoglin-deficient mice. |
cDNA microarray, quantitative mass spectrometry, siRNA knockdown of endoglin and ALK1, hindlimb ischemia mouse model |
Blood |
Medium |
23018639
|
| 2013 |
BMP9 promotes proliferation and survival (anti-apoptotic function) in HepG2 hepatocellular carcinoma cells via autocrine signaling, activating Smad1/5/8 phosphorylation and Id1 upregulation; BMP9 also triggers cell cycle progression in these cells. |
siRNA knockdown, chemical inhibitors (ligand trap), proliferation assays, apoptosis assays (low-serum), Smad1/5/8 phosphorylation western blot |
PloS one |
Medium |
23936038
|
| 2013 |
BMP9 controls lymphatic vessel maturation and valve formation via ALK1; Bmp9-KO mice show hyperplastic mesenteric collecting vessels retaining LYVE-1 expression, and BMP9 inhibits LYVE-1 expression in lymphatic endothelial cells in an ALK1-dependent manner. BMP9 upregulates valve formation genes (Foxc2, Connexin37, EphrinB2, Neuropilin1) in LECs. |
Bmp9-KO mice, lymphatic vessel morphometry, in vitro LEC treatment with BMP9, ALK1 dependency confirmed by inhibition, lymphatic drainage assay |
Blood |
High |
23741013
|
| 2014 |
BMP9 induces VSMC osteogenic differentiation and calcification via ALK1 and Smad-dependent pathways; BMP9 activates Smad1/5/8 and Smad2/3 phosphorylation, both of which bind Smad4 to activate target genes. Smad4 siRNA knockdown significantly reduces BMP9-induced ALP activity and calcium deposition. |
In vitro VSMC calcification assay, soluble ALK1 chimeric protein inhibition, Smad siRNA, ALP inhibitor, western blot for Smad phosphorylation |
Journal of cellular and molecular medicine |
Medium |
25297851
|
| 2014 |
BMP9 stability and activity are regulated by a redox-dependent mechanism: BMP9 dimers form with (D-form, disulfide-bonded) or without (M-form) an intermolecular disulfide bond, resolved by a 1.9 Å crystal structure. The M-form shows less sustained Smad1/5/8 phosphorylation and greater susceptibility to redox-dependent protease cleavage from serum. |
Chromatography, X-ray crystallography (1.9 Å), redox conversion assays, Smad1/5/8 phosphorylation kinetics, protease susceptibility assays |
The Journal of biological chemistry |
High |
25237187
|
| 2014 |
BMP9 potently suppresses FSH-induced progesterone production in rat granulosa cells via a receptor complex of ALK1 and BMPR-II, activating Smad1/5/8 phosphorylation and Id-1 transcription; actions are not mediated by ALK2, ALK3, or ALK6 based on inhibitor analysis. |
Rat primary granulosa cell culture, ALK inhibitors, extracellular domain receptor constructs for receptor identification, Smad1/5/8 phosphorylation assay, cAMP measurement, steroidogenic gene expression |
The Journal of steroid biochemistry and molecular biology |
Medium |
25527306
|
| 2015 |
BMP9 and BMP10 are required for ductus arteriosus closure; Bmp9-KO mice show imperfect DA closure, and combined BMP10 neutralization causes reopening. The mechanism involves a defect in intimal cell differentiation from endothelium to mesenchyme with lack of extracellular matrix deposition; several genes involved in this process are regulated by BMP9 and BMP10. |
Bmp9-KO mice, neutralizing anti-BMP10 antibody, transmission electron microscopy, immunofluorescence, gene expression analysis |
Proceedings of the National Academy of Sciences of the United States of America |
High |
26056270
|
| 2015 |
DLL4/Notch1 and BMP9/ALK1 signaling pathways are interdependent for induction of endothelial quiescence: canonical BMP9 signaling via ALK1-Smad1/5/9 is disrupted by Notch inhibition, and DLL4 activity is suppressed when basal ALK1-Smad pathway is inhibited. The combined pathway acts through P27KIP1 induction and thrombospondin-1 upregulation. Loss of Dll4 in vivo leads to compensatory upregulation of pSmad1/5/9. |
Human endothelial cell culture, Notch inhibitors, ALK1-Smad pathway inhibitors, proteomics, Dll4(+/-) mouse lung endothelial cell analysis |
Arteriosclerosis, thrombosis, and vascular biology |
Medium |
26471266
|
| 2015 |
BMP9-induced endothelial quiescence requires endoglin expression; endoglin regulates subcellular localization of zyxin in focal adhesions in response to BMP9. BMP9-dependent nuclear localization of YAP1 (Hippo pathway transcriptional coactivator) occurs via endoglin, modulating expression of CCN1, CCN2, and CCL2. |
RNA knockdown of endoglin, confocal immunofluorescence of zyxin/YAP1 localization, gene expression analysis (YAP1 target genes) |
PloS one |
Medium |
25909848
|
| 2015 |
BMP9 induces EPC-to-endothelial cell differentiation and neovascularization via ALK1; blockade of ALK1 signaling impairs EPC-mediated neovascularization in a hindlimb ischemia model. |
Gene expression profiling of EPCs, in vitro ALK1-dependent differentiation assay, hindlimb ischemia mouse model, ALK1 signaling blockade |
Arteriosclerosis, thrombosis, and vascular biology |
Medium |
26229139
|
| 2015 |
In ovarian and breast epithelial cells, GDF2/BMP9 activates the SMAD1/5 signaling axis through increased complex formation between ALK3/ALK6 (type I receptors) and BMPRII (type II receptor); this activation promotes anoikis sensitivity and suppresses anchorage-independent growth, independent of SMAD2 cross-talk. GDF2 promoter methylation silences this tumor-suppressive function in cancer cell lines. |
Receptor co-immunoprecipitation, SMAD1/5 phosphorylation assays, anchorage-independent growth assays, promoter methylation analysis |
Neoplasia (New York, N.Y.) |
Medium |
26678910
|
| 2017 |
Crystal structure of the human endoglin ectodomain in complex with BMP9 resolved; BMP9 interacts with a hydrophobic surface of the N-terminal orphan domain of endoglin. The interface involves HHT1-mutated residues and overlaps with the TRC105 antibody epitope. Structurally, two endoglin copies embrace homodimeric BMP9 in a manner compatible with type I but not type II receptor binding. |
X-ray crystallography of ENG ectodomain and ENG:BMP9 complex |
Cell reports |
High |
28564608
|
| 2017 |
BMP9 stimulates ET-1 release from human pulmonary artery endothelial cells via Smad1 and p38 MAPK, independent of the canonical Smad4 pathway; ALK1 or BMPR-II knockdown attenuates BMP9-stimulated ET-1 release. BMP9-induced ET-1 is involved in inhibition of endothelial cell migration and promotion of tubule formation. |
Western blot, RT-PCR, ELISA, siRNA knockdown of ALK1 and BMPR-II, migration assay, tubule formation assay |
PloS one |
Medium |
22299030
|
| 2017 |
BMP9 promotes liver fibrosis via SMAD/ID1 signaling directly in hepatic stellate cells; hepatic stellate cells (quiescent and activated) are identified as major BMP9-producing cells in the liver. Adenovirus-mediated Bmp9 knockdown or BMP9 antagonist ALK1-Fc attenuates fibrosis in chronic liver injury mouse models. |
Primary liver cell culture, BMP9 stimulation of HSCs and hepatocytes, partial hepatectomy and CCl4 mouse models, adenoviral Bmp9 knockdown, anti-BMP9 monoclonal antibody, SMAD signaling western blot |
Gut |
High |
28336518
|
| 2018 |
BMP9/ALK1 signaling prevents hyperglycemia-induced vascular permeability by preventing VEGF-induced VE-cadherin phosphorylation and by inducing occludin expression; ALK1 haploinsufficiency worsens vascular leakage in diabetic mice, and adenoviral BMP9 delivery reduces retinal barrier dysfunction. |
In vitro hyperglycemic endothelial cell model, streptozotocin diabetic mouse model, Alk1 haploinsufficient mice, adenoviral BMP9 delivery, VE-cadherin phosphorylation western blot, occludin expression assay |
Arteriosclerosis, thrombosis, and vascular biology |
Medium |
29880487
|
| 2018 |
BMP9-induced osteoblastic differentiation in MSCs requires functional Notch signaling; Notch inhibitor and dominant-negative Notch1 inhibit BMP9-induced osteogenic differentiation in vitro and ectopic bone formation in vivo. BMP9 upregulates expression of Notch receptors and ligands at the intermediate stage of osteogenic differentiation, while early-responsive BMP9 target genes are not affected by Notch disruption. |
Notch inhibitor treatment, dominant-negative Notch1 expression, Notch pathway genetic disruption, in vivo ectopic bone formation, gene expression analysis |
Laboratory investigation |
Medium |
30353129
|
| 2019 |
Soluble endoglin (sENG) purified from human placenta and plasma is primarily monomeric; monomeric sENG binds circulating prodomain-bound BMP9, causing prodomain release and formation of a sENG:BMP9 complex. This complex signals with comparable potency and specificity to BMP9 alone on endothelial cells; full signaling requires transmembrane ENG. Thus sENG does not act as an inhibitory ligand trap for BMP9. |
Protein purification, biochemical characterization (size exclusion chromatography), in vitro endothelial cell signaling assay, prodomain release assay |
Proceedings of the National Academy of Sciences of the United States of America |
High |
31431534
|
| 2019 |
Loss of BMP9 (genetic deletion or antibody neutralization) substantially protects against chronic hypoxia-induced pulmonary hypertension in mice. BMP9 affects the balance between endothelin-1, apelin, and adrenomedullin in pulmonary endothelial cells; Bmp9-/- mice show lower ET-1 and higher apelin/ADM mRNA. BMP9-mediated vasoconstriction is inhibited by the endothelin receptor antagonist bosentan. |
Bmp9-/- mouse model, neutralizing anti-BMP9 antibodies, ALK1ECD ligand trap in monocrotaline/SuHx rat models, right ventricular systolic pressure measurement, in vitro human pulmonary endothelial cells, chick chorioallantoic membrane assay |
Circulation research |
High |
30636542
|
| 2019 |
BMP9 mutations (missense) identified in IPAH patients impair BMP9 secretion and reduce anti-apoptotic activity in pulmonary arterial endothelial cells; patients with BMP9 mutations have lower plasma BMP9 levels. |
Exome sequencing, in vitro mutant protein expression, secretion assay, apoptosis assay in PAECs, plasma BMP9 ELISA |
The European respiratory journal |
Medium |
30578397
|
| 2020 |
Crystal structures of BMP10:ALK1 complex (2.3 Å) and prodomain-bound BMP9:ALK1 complex (3.3 Å) reveal a tripartite recognition mechanism defining BMP9/BMP10 specificity for ALK1. Introduction of BMP10-specific residues into BMP9 yields ligands with diminished C2C12 signaling, validating the mechanism. Crossveinless 2 is predicted and experimentally confirmed not to inhibit BMP9. |
X-ray crystallography (2.3 Å and 3.3 Å), mutagenesis (BMP10 residues introduced into BMP9), C2C12 signaling assay, in vivo bone formation assay |
Nature communications |
High |
32238803
|
| 2020 |
GDF2 missense mutations found in PAH patients cause impaired BMP9 cellular processing and secretion; patients carrying these mutations have reduced plasma BMP9 levels and reduced BMP activity. Unexpectedly, plasma BMP10 levels are also markedly reduced in individuals with GDF2 mutations. |
In vitro mutant BMP9 protein expression, secretion assay, plasma ELISA for BMP9 and BMP10, endothelial Smad signaling bioassay |
American journal of respiratory and critical care medicine |
Medium |
31661308
|
| 2020 |
BMP9 and BMP10 act directly on vascular smooth muscle cells (VSMCs) via ALK1 to induce and maintain the contractile state; combined genetic inactivation of Bmp9 and Bmp10 causes decreased systemic blood pressure and diminished VSMC layer. ALK1 deletion in VSMCs recapitulates the Bmp9/10 phenotype in pulmonary but not aortic arteries, indicating vessel-bed specific receptor combinations. |
Cell-type specific conditional KO mouse models, blood pressure measurement, pulmonary VSMC isolation and phenotypic analysis, single molecule FISH, bulk RNA-seq, Smad7 VSMC-specific overexpression |
Circulation |
High |
33334130
|
| 2020 |
BMP9-induced ALK1 endocytosis in endothelial cells is mediated by caveolin-1 (CAV-1) and dynamin-2 (DNM2) but not clathrin; knockdown of CAV-1 reduces BMP9-mediated ALK1 internalization, BMP9-dependent Smad1/5 signaling and gene expression. BMP9 treatment strongly reduces LDL transcytosis via ALK1 internalization. |
Endothelial cell imaging, siRNA knockdown of CAV-1/DNM2/clathrin, SMAD1/5 phosphorylation western blot, LDL transcytosis assay |
The Journal of biological chemistry |
Medium |
33097593
|
| 2020 |
CRISPR-mediated BMP9 ablation in mice causes hepatosteatosis due to downregulated PPARα expression and reduced fatty acid oxidation; BMP9 activates PPARα promoter activity via p-Smad signaling. AAV-mediated BMP9 overexpression in mouse liver relieves liver steatosis. |
CRISPR BMP9 knockout mice, lipid accumulation assays, PPARα promoter activity assay, p-Smad western blot, PPARα antagonist GW6471, AAV-mediated overexpression |
Science advances |
High |
33246954
|
| 2020 |
BMP9 and BMP10 repress basal CCL2 expression and release from human pulmonary artery and aortic endothelial cells via ALK1, co-dependent on ACTR-IIA and BMPR-II, and requiring Smad4; Smad1/5 signaling contributes only at near-circulating BMP9 concentrations. |
siRNA knockdown of ALK1, ACTR-IIA, BMPR-II, Smad4; Smad1/5 inhibition; CCL2 ELISA; Smad signaling western blot |
Journal of cell science |
Medium |
32576665
|
| 2021 |
Endogenous circulating BMP9 is a pulmonary endothelial-protective factor that maintains vascular barrier function; BMP9 neutralization in mice increases lung vascular permeability, interstitial edema, and neutrophil extravasation. During LPS-induced lung injury, circulating BMP9 is markedly reduced due to decreased hepatic BMP9 mRNA and increased elastase activity. Exogenous BMP9 prevents LPS-induced lung injury. |
BMP9-neutralizing antibody in mice, lung vascular permeability assay, neutrophil extravasation measurement, murine acute lung injury (inhaled LPS) model, hepatic BMP9 mRNA quantification, plasma elastase activity, patient plasma BMP9 ELISA |
American journal of respiratory and critical care medicine |
High |
33320799
|
| 2021 |
Homozygous GDF2 nonsense mutations result in undetectable plasma BMP9 and BMP10 levels, demonstrating that loss of circulating BMP9 also abolishes circulating BMP10; heterozygous carriers have reduced but functional BMP9/BMP10 levels. Alternate translation at Met57 in one nonsense mutant does not yield secreted functional BMP9. |
Plasma ELISA for BMP9 and BMP10, endothelial BRE-luciferase reporter serum bioassay, in vitro mutant protein expression and secretion assay |
Molecular genetics & genomic medicine |
Medium |
33834622
|
| 2021 |
BMP9 reduces osteoblast senescence by activating Smad1, which suppresses STAT1 transcriptional activity and thereby inhibits P21 expression and SASP production; this Smad1-Stat1-P21 axis mediates BMP9's protection against age-related bone loss in aged mice. |
Aged mouse model, Smad1 signaling inhibition in vivo, Stat1 and P21 expression analysis, SASP markers, bone mass measurement |
Cell death discovery |
Medium |
35523787
|
| 2021 |
BMP9-ID1 signaling promotes EpCAM-positive HCC cancer stem cell properties via enhancing Wnt/β-catenin signaling; ID1 knockdown represses BMP9-promoted HCC-CSC properties. BMP receptor inhibitors (K02288, LDN-212854) block BMP9-ID1 signaling and suppress HCC tumor growth in vivo. |
siRNA knockdown of ID1, BMP receptor inhibitor treatment, EpCAM/ID1 expression, in vivo HCC xenograft, Wnt/β-catenin signaling assay |
Molecular oncology |
Medium |
33834612
|
| 2022 |
FOXF1 transcription factor activates BMP9/ACVRL1/SMAD1 signaling in pulmonary endothelial progenitor cells; FOXF1 synergizes with ETS transcription factor FLI1 to activate the ACVRL1 promoter. Nanoparticle-mediated ACVRL1 silencing in newborn mice decreases neonatal lung angiogenesis, and exogenous BMP9 restores angiogenesis in ACVRL1-deficient and Foxf1 mutant mice. |
scRNA-seq, Foxf1 mutant mice (ACDMPV model), ACVRL1 promoter activation assay, nanoparticle siRNA knockdown in neonatal mice, BMP9 rescue treatment |
Nature communications |
High |
35440116
|
| 2022 |
BMP10 is the critical physiological ligand for ENG-ALK1 arteriovenous network formation, while BMP9 has limited compensatory function; Bmp10-iKO mice develop AVMs while Bmp9-KO mice show no noticeable vascular defects. BMP10 protein (but not BMP9 protein) prevents retinal AVM in Bmp9/10-dKO and endothelial Eng-iKO mice. |
Conditional Bmp10-iKO and Bmp9/10-dKO mouse models, retinal vascular morphometry, brain/skin AVM analysis, BMP9 and BMP10 protein rescue injections |
Angiogenesis |
High |
36348215
|
| 2024 |
BMP9 and BMP10 activate a non-canonical transcriptional SMAD-dependent MAPK pathway (MEKK4/GADD45β/P38) in endothelial cells, which is required for expression of GADD45β; activated P38 phosphorylates HSP27 and Eps15, and regulates specific gene expression (E-selectin, hyaluronan synthase 2, COX-2). BMP10 induces G1 cell cycle arrest by modulating CDK4/6 pathway and inhibiting E2F2, cyclinD1, cyclinA1 mRNA expression. |
Large-scale phosphoproteomics, western blot validation of phosphosites, RT-qPCR, flow cytometry cell cycle analysis |
Cell communication and signaling |
Medium |
38439036
|
| 2021 |
A heterozygous GDF2 variant causes HHT with pulmonary AVMs; in vitro, the mutant construct expresses the proprotein but lacks active mature BMP9 dimer, indicating the mutation disrupts correct protein cleavage. Plasma BMP9 levels in patients are significantly lower than controls. |
In vitro mutant BMP9 expression, protein processing/cleavage assay, plasma BMP9 ELISA |
American journal of medical genetics. Part A |
Medium |
34904380
|